In short: Two regulatory legs moved on the Kimberly-Clark (KMB) acquisition in the same week — one cleared with a remedy, one newly started. "Kenvue received approval from the NZ Commerce Commission subject to divesting the Kenvue feminine hygiene business," and "the EC commenced its review of the Kenvue / Kimberly-Clark transaction with the phase one deadline set for September 29th." A divestiture-conditioned clearance in a small jurisdiction is usually a template for what the larger regulators will ask for; the European Phase 1 date is now the deal's next binary.
Kenvue — the consumer-health business spun out of Johnson & Johnson — is being acquired by Kimberly-Clark, and two regulatory legs moved this week in opposite directions.
New Zealand cleared the deal, but only on condition that Kenvue's feminine-hygiene business is sold. That is the more informative event: a conditional clearance in a small jurisdiction usually previews what larger regulators will ask for, because the competitive overlap that troubled New Zealand exists everywhere the two companies both sell.
Meanwhile the European Commission formally opened its review, with a first-phase deadline of 29 September. That date is now the deal's next binary: clearance at phase one means it proceeds, while a referral to a second-phase investigation would add many months and widen the spread.
Full passage: premium transcript (PDF).
In short: Another cleared leg: "Kenvue received the approval from the Mexico competition authority."
Full passage: premium transcript (PDF).
In short: News segment (Dom Chu), no committee stance: a federal appellate court revived some Tylenol/acetaminophen–autism/ADHD lawsuits; Kenvue's statement says "credible independent science shows no proven link" and it will keep defending. Shares ~−2% at session lows.
Nothing matches this filter.
Verbatim excerpts from the public transcripts (auto-pulled at each mention's timestamp, lightly cleaned). Timestamps link into the video; "source page" opens that commentator's full analysis at this row. Click a mention's header line to expand it (one open at a time). For personal study — not investment advice.